A5042174915- Lymphoma Diagnosis and Treatment
- Cardiovascular and exercise physiology
- Lipoproteins and Cardiovascular Health
- Colorectal Cancer Treatments and Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Heart Rate Variability and Autonomic Control
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Antiplatelet Therapy and Cardiovascular Diseases
- Hemodynamic Monitoring and Therapy
- Dialysis and Renal Disease Management
- Adipokines, Inflammation, and Metabolic Diseases
- Lung Cancer Treatments and Mutations
- Inflammatory Biomarkers in Disease Prognosis
- Stress Responses and Cortisol
- Chronic Kidney Disease and Diabetes
- Eosinophilic Disorders and Syndromes
- Pituitary Gland Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Pharmaceutical Economics and Policy
- Renal Transplantation Outcomes and Treatments
- Pharmacological Effects and Assays
- Viral-associated cancers and disorders
- Cancer therapeutics and mechanisms
CSL (United States)
2021-2024
CSL (Australia)
2021
Teva Pharmaceuticals (United States)
2012-2014
Thomas Jefferson University
1981-1989
Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in phase 2b dose-finding study. Adults disease and/or diabetes receiving maintenance dialysis high-sensitivity C-reactive protein (hs-CRP) ≥ 2 mg l
Summary JAK 2‐ V617F is central to the pathogenesis of myeloproliferative neoplasms. We examined whether lestaurtinib decreased allele burden and evaluated its clinical benefits tolerability in patients with polycythaemia vera ( PV ) essential thrombocythaemia ET ). This phase 2, open‐label, multicentre study was designed detect ≥15% reduction 15% patients. Eligible received 80 mg twice daily for 18 weeks could participate a 1‐year extension treatment. Of 39 enrolled patients, 27 (69%) had ;...
Fluocortinbutyl (FCB) is a C-21 ester, topically active corticosteroid; no adrenal suppression has been noted after large doses. We compared safety and effects on adrenocortical function of orally inhaled FCB (40 mg/day), beclomethasone dipropionate (BDP) (2 placebo administered in four monitored divided doses for 4 wk by three groups five healthy men. Circadian plasma Cortisol concentrations daily urinary free cortisol excretion were determined before 3- 4-wk exposure. Although pretreatment...
Abstract CSL112 (apolipoprotein A‐I [apoA‐I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study aimed compare pharmacokinetics (PKs), pharmacodynamics (PDs), and safety Japanese White subjects. A total 34 subjects were randomized receive single infusion (2, 4, or 6 g) placebo 18 dose g placebo, followed PK/PD assessment adverse monitoring. In...
8537 Background: BR was previously reported to be statistically noninferior R-CVP/R-CHOP for complete response rate in the treatment of patients with indolent NHL or MCL. Evaluation time-to-event outcomes is immature. This subanalysis reports by histology. Methods: Indolent MCL histologically confirmed <6 months before study enrollment who were therapy-naïve. Patients stratified according predetermined standard (R-CHOP RECVP) and lymphoma type, then assigned receive (28-day cycles:...
This study evaluated the effects of single doses angiotensin converting enzyme inhibitor captopril and beta‐adrenergic blocking agent propranolol, alone or in combination, on blood pressure, heart rate humoral responses to both isometric (handgrip) dynamic (ergometric) exercise normotensive hypertensive men. Single oral either placebo, 50 mg, propranolol 80 latter two combination were administered age‐matched groups (n = 5) men a random, double‐blind manner. Captopril was indistinguishable...
8565 Background: The BRIGHT study demonstrated that first-line BR was non-inferior to R-CHOP/R-CVP in terms of complete remission rate indolent NHL and MCL. This is the first detailed analysis safety tolerability regimens. Methods: Patients were preselected for R-CHOP or R-CVP, then randomized 6-8 cycles (28-d cycle) standard regimen (21-d cycles). dosing bendamustine 90 mg/m 2 /d as a 30-min infusion on days 1 plus rituximab 375 given before day 1. Colony stimulating factors (CSFs)...
Bucindolol is an investigational beta‐adrenergic blocking agent with intrinsic sympathomimetic and vasodilatory activity in animals. In a double‐blind, six‐way, crossover study of six mild‐to‐moderate hypertensive men, the effects bucindolol 100, 200, 300 mg/d on resting blood pressure, heart rate, forearm flow, vascular resistance measured by pneumoplethysmography, pressure rate after cycle handgrip exercise were compared those propranolol 160 320 placebo q12h administration for five doses....
Abstract Background CSL112 (apolipoprotein A-I [human]) is a novel therapy designed to reduce the risk of recurrent cardiovascular events following acute myocardial infarction (AMI). Preclinical data suggest that apolipoprotein has anti-inflammatory properties which might contribute atherosclerotic plaque stabilization (1). The neutrophil-lymphocyte ratio (NLR) clinically accessible measure inflammatory status and predicts incident in large outcome trials (2). It unknown whether can...
9547 Background: The PK profile of bendamustine in adult patients is well characterized. objective this analysis was to describe the pediatric relative and correlate systemic exposure efficacy safety parameters. Methods: Samples were obtained after a single dose from aged 1-19 years with relapsed/refractory acute leukemia who enrolled an open-label, nonrandomized study (90–120 mg/m 2 , infused over 60 minutes). prior infusion preselected time points through 24 hours start on day 1....
This study evaluated the effects of single doses angiotensin converting enzyme inhibitor captopril and beta‐adrenergic blocking agent propranolol, alone or in combination, on blood pressure, heart rate humoral responses to both isometric (handgrip) dynamic (ergometric) exercise normotensive hypertensive men. Single oral either placebo, 50 mg, propranolol 80 latter two combination were administered age‐matched groups (n = 5) men a random, double‐blind manner. Captopril was indistinguishable...